Location
Headquarters: Hamburg, Hamburg, Germany, Europe
Region: Hamburg
Country: DE
Continent: Europe
About
Evotec is a global biotechnology company pioneering the future of drug discovery and preclinical development. They strive for technology and science leadership in everything they do and accelerate the journey from concept to cure by leveraging cutting-edge technology, disruptive science, and extensive disease knowledge in collaboration with partners. Their expertise spans across modalities from small molecules to biotherapeutics, and through Just – Evotec Biologics they have advanced biologics design, development, and manufacturing. Evotec operates with a fully integrated R&D value chain and flexible partnering models to deliver speed, efficiency, and quality in bringing medicines to patients.
Evotec is a biotechnology company providing integrated drug discovery and development services to pharmaceutical and biotech partners. It operates a Pipeline Co-Creation model that spans from target discovery to clinical proof of concept and commercial manufacturing. The firm leverages AI and data-driven science across small molecules and biotherapeutics to accelerate medicine development.
Evotec SE
2014
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Grant
78800000
200m-1b
ipo
FRA:EVT
nasdaq
Investors
Founders
Charles Weissmann
Freimut Leidenberger
Heinrich M. Schulte
Karsten Henco
Manfred Eigen
Rudolf Rigler
Ulrich Aldag
Leadership
Technology Stack
Products
Pipeline Co-Creation Partnerships: Collaborative partnerships to co-create drug discovery pipelines from disease understanding to clinical phases, focusing on small molecules and biotherapeutics.
Contract Research Organization (CRO) Services: Research services supporting drug discovery and development, including preclinical studies and safety assessments.
Contract Development and Manufacturing Organization (CDMO) Services: Development and manufacturing services for biotherapeutics, including continuous manufacturing technologies.
PanOmics Platform: An AI-powered proprietary platform integrating multi-omics data to improve disease understanding and drug discovery.
Induced Pluripotent Stem Cell (iPSC) Technologies: Use of iPSC-derived cell models to improve human relevance in drug discovery and safety testing.
Cardiotox Screen Assay: In vitro assay assessing functional and structural cardiotoxicity of compounds using phenotypic profiling and calcium transient analysis.
Funding rounds
Grant · $9.9M · (2026-04-30) · Lead: Bill & Melinda Gates Foundation
Grant · $2.5M · (2025-05-07) · Lead: Bill & Melinda Gates Foundation
Grant · (2025-01-22) · Lead: Korea Advanced Institute of Science and Technology
Connect
Connect
Open positions(8)
- Scientist - Site Based, Princeton, NJFull-timeWork from OfficePrinceton, NJ66,375–90,325 / Year
- Associate Principal Scientist - In Vitro Toxicology - Microelectrode Array - Site Based, Princeton, NJFull-timeWork from OfficePrinceton, NJ93,500–115,000 / Year
- Associate Principal Scientist - In Vitro Toxicology - Microelectrode Array - Site Based, Princeton, NJFull-timeWork from OfficePrinceton, NJ93,500–115,000 / Year
- Associate ScientistContractWork from OfficeAlderley Park
- Associate Principal Scientist_ToxFull-timeWork from OfficePrinceton, NJ93,500–126,500 / Year
- Associate Principal Scientist_ToxFull-timeWork from OfficePrinceton, NJ93,500–126,500 / Year
- Associate Principal Scientist - In Vitro Toxicology - Microelectrode Array - Site Based, Princeton, NJFull-timeWork from OfficePrinceton, NJ93,500–115,000 / Year
- Associate Principal Scientist_ToxFull-timeWork from OfficePrinceton, NJ93,500–126,500 / Year